Bone Biologics Corporation Announces New “At the Market” Offering Program and Legal Opinion Filing

Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) has filed a Current Report on Form 8-K dated March 13, 2026, with the U.S. Securities and Exchange Commission (SEC). The filing contains several key developments that are highly relevant for shareholders and could impact the company’s share price and outlook.

Key Highlights of the Report

• Launch of “At the Market” Offering:
  The company announced the filing of a Prospectus Supplement with the SEC in connection with its “at the market offering” program. This program allows Bone Biologics Corporation to offer and sell up to \$1,064,000 of its common stock (par value \$0.001 per share) from time to time through H.C. Wainwright & Co., LLC, acting as the sales agent. The offering will be conducted pursuant to the company’s existing At The Market Offering Agreement dated September 27, 2024.
  This is a price-sensitive event: The ability to issue new shares directly into the market may affect the company’s share price by increasing the supply and providing the company with additional capital for business operations, R&D, or other strategic initiatives.
• Legal Opinion Filed:
  Bone Biologics has filed a legal opinion from Harter Secrest & Emery LLP as Exhibit 5.1. The opinion confirms the legality of the shares to be issued under the Sales Agreement and covered by the Prospectus Supplement. This is a standard step in U.S. capital markets to assure investors that shares issued are valid, fully paid, and non-assessable.
• Summary of Securities Registered:
  • Common Stock (par value \$0.001 per share) – Trading Symbol: BBLG – Listed on Nasdaq Capital Market
  • Warrants to Purchase Common Stock (par value \$0.001 per share) – Trading Symbol: BBLGW – Listed on Nasdaq Capital Market
• Emerging Growth Company Status:
  Bone Biologics indicated that it is not an emerging growth company under Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Exchange Act of 1934. This means the company does not benefit from certain reduced disclosure requirements.
• No Pre-commencement Communications:
  The filing confirms that Bone Biologics is not making written communications, soliciting material, or tender offers as defined by various SEC rules with this Form 8-K.

Details of the Legal Opinion (Exhibit 5.1)

• The legal opinion assures that the 1,064,000 shares to be issued are authorized, validly issued, fully paid, and non-assessable, assuming company compliance with Delaware law, its Certificate of Incorporation and Bylaws, and other standard corporate formalities.
• The opinion is limited exclusively to Delaware General Corporation Law and does not address laws of other jurisdictions.
• The law firm consents to the inclusion of its opinion as an exhibit in the Current Report and the reference to the firm under “Legal Matters” in the Prospectus Supplement.

Potential Implications for Shareholders

• Share Dilution: The “at the market” offering could lead to dilution of existing shareholders if new shares are issued and sold. Investors should monitor subsequent SEC filings for actual share issuances and their impact on the company’s capital structure.
• Capital Raise: The offering provides Bone Biologics with flexibility to raise capital as needed. This could be beneficial for funding growth, product development, or supporting ongoing operations, especially in the biotech/medical device sector where funding is critical.
• Trading Liquidity: The availability of more shares in the market may improve liquidity, but could also exert downward pressure on the share price, depending on market conditions and investor sentiment.
• No Tender Offers or Solicitation: The company is not currently engaging in tender offers or soliciting materials, so investors should not expect any imminent merger, acquisition, or takeover activity based on this filing.

Conclusion

This report contains material information for shareholders. The launch of an “at the market” offering program is a significant event that could impact share price and shareholder value, depending on the timing and size of share issuances. Investors are encouraged to review future filings and monitor the company’s use of proceeds and capital strategy.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making any investment decisions. The author is not responsible for any actions taken based on the information provided above.

View Bone Biologics Corp Historical chart here